The results show benefit from the use of abiraterone in patients with asymptomatic or mildly symptomatic metastatic castration -resistant prostate cancer who have not received previous chemotherapy. These findings include increased rates of radiographic progression-free survival and overall survival, as well as clinically meaningful secondary end points, such as delays in the use of opiates for pain and chemotherapy and patient-reported outcomes related to health-related quality of life.

Awesome Image